TY - JOUR
T1 - Cytomegalovirus vaccine in renal transplant candidates
T2 - Progress report of a randomized, placebo-controlled, double-blind trial
AU - Balfour, H. H.
AU - Sachs, G. W.
AU - Welo, P.
AU - Gehrz, R. C.
AU - Simmons, R. L.
AU - Najarian, J. S.
PY - 1984/12/1
Y1 - 1984/12/1
N2 - Prospective studies now have confirmed that CMV is an important pathogen for renal allograft recipients. Investigations from at least 12 renal transplant centers have provided convincing evidence that CMV is a major posttransplant problem, causing fever, leukopenia, arthralgia, pneumonitis, hepatitis, GI bleeding, encephalitis, retinitis, graft loss, and mortality. In our prospective study of 272 renal allograft recipients, CMV infection occurred after 181 (57%) transplants. Using a multivariate analysis that employed an exponential survival model, CMV was significant risk factor (P <0.05) for posttransplant fever, leukopenia, graft failure, and mortality.
AB - Prospective studies now have confirmed that CMV is an important pathogen for renal allograft recipients. Investigations from at least 12 renal transplant centers have provided convincing evidence that CMV is a major posttransplant problem, causing fever, leukopenia, arthralgia, pneumonitis, hepatitis, GI bleeding, encephalitis, retinitis, graft loss, and mortality. In our prospective study of 272 renal allograft recipients, CMV infection occurred after 181 (57%) transplants. Using a multivariate analysis that employed an exponential survival model, CMV was significant risk factor (P <0.05) for posttransplant fever, leukopenia, graft failure, and mortality.
UR - http://www.scopus.com/inward/record.url?scp=0021752173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021752173&partnerID=8YFLogxK
M3 - Article
C2 - 6329368
AN - SCOPUS:0021752173
SN - 0547-6844
VL - 20
SP - 289
EP - 304
JO - Birth Defects: Original Article Series
JF - Birth Defects: Original Article Series
IS - 1
ER -
